Quetobex XR 50, 150, 200, 300, & 400 50, 150, 200, 300, & 400 mg Prolonged release tablets
PDF Leaflet Revision Date: 05 November 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of schizophrenia, bipolar disorder, and major depressive disorder.
Dosage (summary)
Initial dose for schizophrenia and manic episodes: 300 mg on Day 1, 600 mg on Day 2, up to 800 mg thereafter. For MDD: Start at 50 mg, titrate to 150 mg by Day 3.
Special Populations
- Elderly patients
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; safety not established.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- Alcohol
Contraindications
- Hypersensitivity to quetiapine
- Elderly patients with dementia
- Co-administration with CYP3A4 inhibitors
Common side effects
- Somnolence
- Dizziness
- Weight gain
- Dry mouth
- Constipation
Counselling Points
- Avoid driving if experiencing somnolence
- Monitor for signs of hyperglycemia
- Gradual withdrawal recommended
Serious warnings
- Increased risk of death in elderly patients with dementia
- QT prolongation
- Neutropenia
Important Disclaimer
The Quetobex XR 50, 150, 200, 300, & 400 50, 150, 200, 300, & 400 mg Prolonged release tablets professional information leaflet below is the property of Abex Pharmaceutica and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
